Phase 3 Readout

BBLG: Phase 3 Topline: MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan

Name: Phase 3 Topline: MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan
Start: 2028-03-31
End: 2028-03-31

March 31, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 31, 2028
Company: Bone Biologics Corp (BBLG)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan

March 31, 2028

BBLG overview →

Company: Bone Biologics Corp (BBLG)
Indication: Spinal Deformity; Disc Degeneration